Page last updated: 2024-12-05

monocrotaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4246
CHEMBL ID2134902
CHEBI ID125403
MeSH IDM0025420
PubMed CID9415
CHEMBL ID521035
CHEBI ID6980
SCHEMBL ID164486
MeSH IDM0025420

Synonyms (131)

Synonym
smr001548694
LS-14523
20-norcrotalanan-11,15-dione, 14,19-dihydro-12,13-dihydroxy-, (13.alpha.,14.alpha.)-
nci-c56462
a 6080
mls002639247 ,
nsc 28693
(2,3,4-gh)pyrrolizine-2,6(3h)-dione, (4,5,8,10,12,13,13a,13b)-octahydro-4,5-dihydroxy-3,4,5-trimethyl-2h-(1,6)dioxacycloundecino-
OPREA1_734543
monocrotalin
CHEBI:125403
4,5-dihydroxy-3,4,5-trimethyl-4,5,8,10,12,13,13a,13b-octahydro-2h-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3h)-dione
CHEMBL2134902
12.beta.,13.beta.-dihydroxy-12.alpha.,13.alpha.,14.alpha.-trimethylcrotal-1-enine
4,5-dihydroxy-3,4,5-trimethyl-4,5,8,10,12,13,13a,13b-octahydro-2h-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3h)-dione #
14,19-dihydro-12,13-dihydroxy(13.alpha.,14.alpha.)-20-norcrotalanan-11,15-dione
(13-.alpha.,14-.alpha.)-14,19-dihydro-12,13-dihydroxy-20-norcrotalanan-11,15-dione
QVCMHGGNRFRMAD-UHFFFAOYSA-N
2h-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine, 20-norcrotalanan-11,15-dione deriv.
lsm-36888
Q27215982
14,19-dihydro-12,13-dihydroxy-20-norcrotalanan-11,15-dione, 9ci
A856086
a 6080;a-6080;a6080
BCP04181
(6-chloro-imidazo[1,2-a]pyridin-2-yl)-aceticacid
(2,3,4-gh)pyrrolizine-2,6(3h)-dione,(4,5,8,10,12,13,13a,13b-octahydro-4,5-dihydroxy-3,4,5-trimethyl-2h-(1,6)dioxacycloundecino-
DTXSID20859330
smr001233251
MLS002153902 ,
BRD-K65508953-001-05-5
nsc-28693
KBIO1_000959
DIVK1C_000959
retronecine cyclic 2,3-dihydroxy-2,3,4-trimethylglutarate
(13-alpha,14-alpha)-14,19-dihydro-12,13-dihydroxy-20-norcrotalanan-11,15-dione
SDCCGMLS-0066675.P001
(3r,4r,5r,13ar,13br)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,10,12,13,13a,13b-octahydro-2h-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3h)-dione
CHEBI:6980 ,
ccris 416
12-beta,13-beta-dihydroxy-12-alpha,13-alpha,14-alpha-trimethylcrotal-1-enine
20-norcrotalanan-11,15-dione, 14,19-dihydro-12,13-dihydroxy-, (13-alpha,14-alpha)-
20-norcrotalanan-11,15-dione, 14,19-dihydro-12,13-dihydroxy-, (13alpha,14alpha)-
brn 0048732
hsdb 3513
14,19-dihydro-12,13-dihydroxy(13-alpha,14-alpha)-20-norcrotalanan-11,15-dione
SPECTRUM_001224
ACON0_000305
PRESTWICK_338
jacs 72: 158 (1950)
cas-315-22-0
BPBIO1_000558
BSPBIO_000506
NCGC00179538-01
NCGC00179538-02
MEGXP0_001899
SPECTRUM5_001233
IDI1_000959
ACON1_000179
14,19-dihydro-12,13-dihydroxy-20-norcrotolanan-11,15-dione
monocrotaline
315-22-0
crotaline
PRESTWICK2_000603
NCGC00164256-01
KBIOGR_001354
KBIOSS_001704
KBIO3_002014
KBIO2_006840
KBIO2_004272
KBIO2_001704
SPECTRUM3_000947
SPBIO_002725
PRESTWICK1_000603
SPBIO_000752
SPECTRUM2_000906
SPECTRUM4_001057
NINDS_000959
PRESTWICK0_000603
SPECTRUM1502252
PRESTWICK3_000603
HMS502P21
CHEMBL521035
HMS1569J08
HMS1921P04
NCGC00179538-03
HMS2096J08
NCGC00256518-01
dtxcid50902
tox21_302874
dtxsid9020902 ,
tox21_201509
NCGC00259060-01
tox21_112094
HMS2235J12
S3812
AKOS015969712
CCG-39621
2h-(1,6)dioxacycloundecino(2,3,4-gh)pyrrolizine-2,6(3h)-dione, 4,5,8,10,12,13,13a,13b-octahydro-4,5-dihydroxy-3,4,5-trimethyl-, (3r,4r,5r,13ar,13br)-
4-27-00-06660 (beilstein handbook reference)
unii-73077k8hyv
73077k8hyv ,
(-)-monocrotaline
monocrotaline [mi]
2h-(1,6)dioxacycloundecino(2,3,4-gh)pyrrolizine-2,6(3h)-dione, 4,5,8,10,12,13,13a,13b-octahydro-4,5-dihydroxy-3,4,5-trimethyl-, (3r-(3r*,4r*,5r*,13ar*,13br*))-
monocrotaline [iarc]
monocrotaline [hsdb]
SCHEMBL164486
NCGC00262539-03
tox21_112094_1
AC-34918
Q-100395
2h-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3h)-dione, 4,5,8,10,12,13,13a,13b-octahydro-4,5-dihydroxy-3,4,5-trimethyl-, (3r,4r,5r,13ar,13br)-
CS-6164
HY-N0750
mfcd00084656
SR-01000838886-4
SR-01000838886-3
sr-01000838886
monocrotaline, analytical standard
bdbm50480309
(1r,4r,5r,6r,16r)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0??,??]hexadec-10-ene-3,7-dione
AKOS032962048
Q27107379
BRD-K65508953-001-08-9
FS-5652
109525-74-8
rel-(3r,4r,5r,8a1r,13ar)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,8a1,10,12,13,13a-octahydro-2h-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3h)-dione
(3r,4r,5r,8a1r,13ar)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,8a1,10,12,13,13a-octahydro-2h-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3h)-dione
(1r,4r,5r,6r,16r)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.013,16]hexadec-10-ene-3,7-dione
(3r,4r,8a1r,13ar)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,8a1,10,12,13,13a-octahydro-2h-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3h)-dione

Research Excerpts

Toxicity

Monocrotaline is the major toxic pyrrolizidine alkaloid of Crotalaria species. They induce damages in the central nervous system (CNS), which has been attributed to toxic effects.

ExcerptReferenceRelevance
"The oral LD50 of Crotalaria assamica, which contains mainly monocrotaline, was found to be 154 mg/kg in mice."( A comparative study on the hepatic toxicity and metabolism of Crotalaria assamica and Eupatorium species.
Chan, MY; Ogle, CW; Zhao, XL, 1989
)
0.28
" It is well established that the pneumotoxicity of MCT depends on its hepatic bioactivation to monocrotaline pyrrole (MCTP) and perhaps other toxic metabolites."( Effect of a mixed function oxidase inducer and inhibitor on monocrotaline pyrrole pneumotoxicity.
Bruner, LH; Carpenter, LJ; Hamlow, P; Roth, RA, 1986
)
0.27
" We have hypothesized these lesions to be related to the adverse hepatic actions of MCT and other PAs."( Modulation of monocrotaline-induced hepatic genotoxicity in rats.
Petry, TW; Sipes, IG, 1987
)
0.27
" Monocrotaline is the major toxic pyrrolizidine alkaloid of Crotalaria species."( Effect of 2(3)-tert-butyl-4-hydroxyanisole (BHA) and 2-chloroethanol against pyrrole production and chronic toxicity of monocrotaline in chickens.
Braun, RC; Dickinson, JO, 1987
)
0.27
"This research compared the toxic effects of aflatoxin B1 and monocrotaline, the active principle of Crotalaria spectabilis, and the additive effect between aflatoxin B1 and monocrotaline in turkey poults."( Influence of selenium on aflatoxin B1 or crotalaria toxicity in turkey poults.
Burguera, JA; Edds, GT; Osuna, O, 1983
)
0.27
"When a compound that is removed from the body by metabolism produces toxicity in extrahepatic organs directly, rather than via active metabolites, induction or inhibition of the drug-metabolizing enzymes simply will decrease or enhance, respectively, the toxic effects of the compound."( Effects of inducers and inhibitors on drug-metabolizing enzymes and on drug toxicity in extrahepatic tissues.
Boyd, MR, 1980
)
0.26
" We hypothesized that metabolic activation of MCT by mixed-function oxygenases (MFO) to dehydromonocrotaline (MCTP) is a prerequisite for its immunotoxicity, as has been shown for other toxic effects of MCT."( Role of metabolism in monocrotaline-induced immunotoxicity in C57BL/6 mice.
Buhler, DR; Deyo, JA; Kerkvliet, NI; Reed, RL,
)
0.13
" Azathioprine and monocrotaline were found to be selectively more toxic to SEC than to hepatocytes."( Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease.
DeLeve, LD; Kaplowitz, N; Kuhlenkamp, JF; Wang, X, 1996
)
0.29
" We concluded that, based on markers of endothelial damage, BPAECs showed no apparent ability to metabolize MCT to a reactive intermediate nor to further metabolize GSH-DHP to a toxic species."( Comparative cytotoxicity of monocrotaline and its metabolites in cultured pulmonary artery endothelial cells.
Dunston, SD; Jones, AD; Lamé, MW; Segall, HJ; Taylor, DW; Wilson, DW, 1997
)
0.3
" Because there was no differences on the weight gains and food and water consumption of the dams it is suggested that this toxic effects in the fetuses was caused by the diffusion of MCT through the placenta."( Fetotoxicity and reproductive effects of monocrotaline in pregnant rats.
Górniak, SL; Guerra, JL; Medeiros, RM, 2000
)
0.31
" However, the toxic effects of exposure to MCT in adult rats can be prevented by cysteine."( Lack of protective action of cysteine against the fetotoxic effect of monocrotaline.
Górniak, SL; Guerra, JL; Medeiros, RM; Soto-Blanco, B, 2001
)
0.31
" Pyrrolic metabolites were produced from MCT by SECs in vitro, which suggests that MCT may injure SECs directly through the formation of its toxic metabolite, monocrotaline pyrrole."( Endothelial cell injury and coagulation system activation during synergistic hepatotoxicity from monocrotaline and bacterial lipopolysaccharide coexposure.
Copple, BL; Ganey, PE; Hanumegowda, UM; Roth, RA; Shibuya, M; Yee, SB, 2003
)
0.32
"Isoline, a major retronecine-type pyrrolizidine alkaloid (PA) from the Chinese medicinal herb Ligularia duciformis, was suggested to be the most toxic known PA."( In vitro metabolism of isoline, a pyrrolizidine alkaloid from Ligularia duciformis, by rodent liver microsomal esterase and enhanced hepatotoxicity by esterase inhibitors.
Akao, T; Hattori, M; Nakamura, N; Sasahara, M; Takagawa, K; Tang, J; Wang, ZT, 2007
)
0.34
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" These results suggest that the toxic effect of MCT on hepatocytes may be caused by metabolite-induced mitochondrial energetic impairment, together with a decrease of cellular glutathione and protein thiols."( Cytotoxicity of monocrotaline in isolated rat hepatocytes: effects of dithiothreitol and fructose.
Alves, LC; Garcia, AF; Maioli, MA; Mingatto, FE; Perandin, D; Pereira, FT, 2011
)
0.37
" They induce damages in the central nervous system (CNS), which has been attributed to toxic effects of the pyrrolizidine alkaloid (PA) monocrotaline (MCT)."( Assessment of neurotoxicity of monocrotaline, an alkaloid extracted from Crotalaria retusa in astrocyte/neuron co-culture system.
Costa, Mde F; Costa, SL; El-Bachá, RS; Fragomeni, BO; Junqueira, HA; Nascimento, RP; Pitanga, BP; Silva, AR; Silva, VD; Souza, CS, 2011
)
0.37
"Monocrotaline (MCT) is a kind of toxic retronecine-type pyrrolizidine alkaloids (PAs) from plants of Crotalaria, which can be bio-activated by cytochrome P450 (CYP) enzymes in liver and then induce hepatotoxicity."( Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity.
Jiang, H; Li, L; Peng, X; Sun, S; Tu, M; Wang, K; Wang, R; Zeng, S; Zhou, H, 2013
)
0.39
" We investigated the antioxidant effects of selenium (Se) and vitamin E against the toxic effects of MCT."( Vitamin E and selenium treatment of monocrotaline induced hepatotoxicity in rats.
Canbaz, HT; Cuce, G; Kalkan, S; Sozen, ME; Yerlikaya, FH, 2017
)
0.46
" We have previously demonstrated the sex difference in developmental toxicity and hepatotoxicity in fetal rats exposed to monocrotaline (MCT), a representative toxic PA."( Female-specific activation of pregnane X receptor mediates sex difference in fetal hepatotoxicity by prenatal monocrotaline exposure.
Dai, YG; Fan, CP; Guo, Q; Guo, Y; Liu, J; Qiu, SK; Sun, XX; Wang, H; Wang, YQ; Xiang, E, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"The results suggest that the newly standardized method for quantitative determination of MCT in whole blood is fast, reliable, specific, sensitive, and suitable for pharmacokinetic studies of MCT after intravenous or intragastric administration."( Pharmacokinetics and Bioavailability Study of Monocrotaline in Mouse Blood by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Chen, L; Fan, Z; Geng, P; Lin, G; Liu, J; Wang, X; Weng, Z; Zhang, B, 2018
)
0.48
" The validated method has been successfully applied to study pharmacokinetic behaviors and bioavailability of MCT in rats."( Simultaneous determination of monocrotaline and its N-oxide metabolite in rat plasma using LC-MS/MS: Application to a pharmacokinetic study.
Lin, F; Liu, J; Pan, A; Ye, Y, 2021
)
0.62

Compound-Compound Interactions

In our study, we investigated the efficacy of everolimus in combination with sildenafil on hemodynamic and morphological parameters in rats with monocrotaline-induced pulmonary hypertension (PH)

ExcerptReferenceRelevance
"In our study, we investigated the efficacy of everolimus in combination with sildenafil on hemodynamic and morphological parameters in rats with monocrotaline-induced pulmonary hypertension (PH)."( Effects of everolimus in combination with sildenafil in monocrotaline-induced pulmonary hypertension in rats.
Atli, O; Burukoglu, D; Ilgin, S; Sirmagul, B, 2012
)
0.38
" One of the most promising rodent models of increased pulmonary flow is the unilateral left pneumonectomy combined with a "second hit" of MCT or Sugen."( The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats.
Bisserier, M; Bridges, CR; Fargnoli, AS; Gubara, SM; Hadri, L; Hajjar, RJ; Katz, MG; Sassi, Y, 2019
)
0.51
"This study test was designed to investigate the possible modulatory effect of rapamycin combined with HO-3867 in monocrotaline(MCT)-induced pulmonary arterial hypertension in rats."( The therapeutic effect and mechanism of Rapamycin combined with HO-3867 on monocrotaline-induced pulmonary hypertension in rats.
Chen, W; Chen, Z; Cheng, S; Hu, S; Li, H; Ouyang, M; Peng, H; Xue, J; Yu, S; Zeng, W; Zhang, Y; Zhou, L, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" Monocrotaline-induced pulmonary hypertension is associated with low bioavailability of nitric oxide."( Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs.
Gewitz, MH; Kumar, A; Mathew, R; Rosenfeld, L; Yuan, N,
)
0.13
"The lungs of patients with pulmonary arterial hypertension (PAH) exhibit decreased bioavailability of nitric oxide and downstream signaling through cyclic guanosine monophosphate (cGMP)."( Pulmonary hemodynamic response to acute combination and monotherapy with sildenafil and brain natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension.
Alpert, MA; Carlino, C; Dellsperger, KC; Demarco, VG; Grueber, RE; Heller, RL; Schneider, RI; Tobias, JD, 2010
)
0.36
" bioavailability promoted by the presence of HPβCD in the complex."( Pterostilbene reduces oxidative stress, prevents hypertrophy and preserves systolic function of right ventricle in cor pulmonale model.
Belló-Klein, A; Bianchi, SE; Campos-Carraro, C; Colombo, R; Dos Santos Lacerda, D; Duarte Ortiz, V; Gazzi de Lima-Seolin, B; Linck Bassani, V; Poletto Bonetto, JH; Sander da Rosa Araujo, A; Türck, P, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Inhalable bosentan microparticles with the capability of delivery to the peripheral region of the lungs and enhanced bioavailability have been formulated for PAH."( Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
Kang, JH; Kim, DW; Kim, JY; Kwon, YB; Lee, HJ; Oh, DW; Park, CW; Park, ES; Rhee, YS; Shin, DH, 2021
)
0.62
" The validated method has been successfully applied to study pharmacokinetic behaviors and bioavailability of MCT in rats."( Simultaneous determination of monocrotaline and its N-oxide metabolite in rat plasma using LC-MS/MS: Application to a pharmacokinetic study.
Lin, F; Liu, J; Pan, A; Ye, Y, 2021
)
0.62

Dosage Studied

Study aimed to reveal whether partial pressure of oxygen of blood determined the binding and release of monocrotaline pyrrole from erythrocytes. Compounds from this series showed in vivo activity after SC dosing.

ExcerptRelevanceReference
" At a dosing regimen of KET that inhibited the 5-HT-induced platelet shape change in platelet-rich plasma and the 5-HT-induced increase in perfusion pressure in isolated lungs, KET did not affect the elevation in lung weight or the increased accumulation of 125I-albumin in the lung tissue of MCTP-treated rats."( Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
Ganey, PE; Hadley, KB; Roth, RA; Sprugel, KH, 1986
)
0.27
" Finally, the Tx receptor antagonist L-640,035 was tested using a dosing regimen that reduced the increase in right ventricular pressure caused by a stable endoperoxide analogue in MCTP-treated rats."( Thromboxane does not mediate pulmonary vascular response to monocrotaline pyrrole.
Ganey, PE; Roth, RA, 1987
)
0.27
" Clearance of perfused 5-hydroxytryptamine, a function of pulmonary vascular endothelium, was unaltered in isolated lungs of treated rats until 5 days after dosing but decreased progressively thereafter in the MCT animals and was 24% less than controls by 14 days."( Pneumotoxicity and thrombocytopenia after single injection of monocrotaline.
Bell, TG; Hilliker, KS; Roth, RA, 1982
)
0.26
" In a dosage of 100 micrograms/kg/day, sandostatin significantly reduced right ventricular systolic pressure, the mass ratio of the right ventricular free wall to the left ventricle, the right ventricular wall thickness, the right ventricular myofiber diameter, the percent medial pulmonary artery thickness, the percent area of smooth muscle cell, and proliferating cell nuclear antigen activity."( Sandostatin inhibits development of medial proliferation of pulmonary arteries in a rat model of pulmonary hypertension.
Imai, S; Kanda, T; Murata, K; Suzuki, T; Takahashi, T, 1995
)
0.29
" The light microscopic appearance and collagen staining of the lungs of the dually treated rats were similar to the negative control rat lungs 2 weeks after dosing with 3-MI."( Manipulation of injury and repair of the alveolar epithelium using two pneumotoxicants: 3-methylindole and monocrotaline.
Segall, HJ; Wilson, DW; Woods, LW, 1999
)
0.3
" A similar DNA adduct profile was detected in the livers of female F344 rats fed riddelliine, and a dose-response relationship was obtained for the level of the total (eight) DHR-derived DNA adducts and the level of the DHR-3'-dGMP adducts."( Metabolic activation of the tumorigenic pyrrolizidine alkaloid, riddelliine, leading to DNA adduct formation in vivo.
Chan, PC; Chou, MW; Doerge, DR; Fu, PP; Yan, J; Yang, YC, 2001
)
0.31
" Similar direct comparative studies in other models of PH and with various dosage regimens are warranted to define the optimal pharmacological approach of PH when ET receptor antagonists are used."( Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.
Cernacek, P; Dupuis, J; Jasmin, JF; Lucas, M, 2001
)
0.31
" Using this latter dosing regimen, animals became moribund as early as 4 h after MCT administration."( The temporal relationship between bacterial lipopolysaccharide and monocrotaline exposures influences toxicity: shift in response from hepatotoxicity to nitric oxide-dependent lethality.
Copple, BL; Ganey, PE; Roth, RA; Yee, SB, 2002
)
0.31
" The mPAP in rats of the double dosage and single dosage of CMOC groups were (26."( [The effect of compound macrostem onion capsule on metabolism of arachidonic acid in a rat model of monocrotaline-induced pulmonary artery hypertension].
Jiang, J; Shang, N; Sun, JG; Xi, ZQ; Zou, X, 2005
)
0.33
" Five groups of rats were studied: controls; rats dosed with MCT (60 mg."( Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats.
Decante, B; Dorfmuller, P; Eddahibi, S; Herve, P; Humbert, M; Le Pavec, J; Lebrec, D; Mazmanian, M; Perros, F; Sitbon, O, 2009
)
0.35
" This dosage also decreased pERK1/2 levels and inhibited proliferation of pulmonary arterial smooth muscle cells in MCT-treated rats."( Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han, DD; Liu, JR; Wang, HL; Wang, Y; Zhang, XH, 2012
)
0.38
" The EMP levels in HGF group which at 7 and 14 days after dosing were significantly decreased compared with PAH."( [Hepatocyte growth factor intervention on rats with pulmonary hypertension and effect of endothelial cell membrane microparticles].
Chen, J; He, Z; Liu, Z; Wang, J; Yang, Y; Zhang, R, 2014
)
0.4
" Compounds from this series showed in vivo activity after SC dosing in the monocrotaline model of PAH in rat."( Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat.
Adams, JW; Boatman, PD; Chang, S; Choi, J; Kramer, B; Martens, P; Morgan, M; Ramirez, J; Semple, G; Shi, Y; Shin, YJ; Shu, HH; Tran, TA; Tung, SF; Unett, DJ; Vallar, P; Zou, N, 2015
)
0.42
" Additionally, in order to evaluate the effects of repeated dosing periods on MN inducibility, a double-dose examination of MCT at doses of 15, 30 and 60mg/kg/day in juvenile (26-days old) and young adult (7-weeks old) rats was also conducted, as an acute dose MN assay."( Micronucleus induction in rat liver and bone marrow by acute vs. repeat doses of the genotoxic hepatocarcinogen monocrotaline.
Hamada, S; Hattori, A; Kawabata, M; Nakadate, K; Nakagawa, M; Takasawa, H; Takashima, R; Wako, Y; Yasunaga, K, 2015
)
0.42
" Overall, CAR-modified-liposomes of SOD plus fasudil, given every 72 h, was as efficacious as plain drugs, given every 48 h, suggesting that the formulation can reduce the total drug intake, systemic exposures, and dosing frequency."( Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
Ahsan, F; Gupta, N; McMurtry, IF; Nozik-Grayck, E; Rashid, J; Stenmark, KR, 2017
)
0.46
" However, the effect of low dosage and transfusion timing of hUCB-MSCs on PAH has not yet been clearly established."( Optimal Dose and Timing of Umbilical Stem Cells Treatment in Pulmonary Arterial Hypertensive Rats.
Choi, SJ; Hong, YM; Kim, KC; Lee, H, 2017
)
0.46
" Thus, OCA dosing in a therapeutic protocol restores the balance between relaxant and contractile pathways in the lung, promoting cardiopulmonary protective actions in MCT-induced PAH."( Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
Adorini, L; Cellai, I; Comeglio, P; Corno, C; Filippi, S; Maggi, M; Morelli, A; Sarchielli, E; Vannelli, GB; Vignozzi, L, 2019
)
0.51
" This study aimed to reveal whether partial pressure of oxygen of blood determined the binding and release of monocrotaline pyrrole from erythrocytes in rats with one subcutaneous injection of monocrotatline at the standard dosage of 60 mg/kg."( Monocrotaline pyrrole induces pulmonary endothelial damage through binding to and release from erythrocytes in lung during venous blood reoxygenation.
Dupuis, J; Fang, J; Hu, Q; Jing, ZC; Li, J; Lu, Y; Luo, S; Su, Y; Wang, T; Xiao, R; Zhang, J; Zhu, L, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pyrrolizines
pyrrolizidine alkaloidAn alkaloid based on the structure of pyrrolizidine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency6.15900.000811.382244.6684AID686978; AID686979
gemininHomo sapiens (human)Potency0.65130.004611.374133.4983AID624297
Chain A, Beta-lactamaseEscherichia coli K-12Potency2.51190.044717.8581100.0000AID485294
RAR-related orphan receptor gammaMus musculus (house mouse)Potency29.84930.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency14.91040.000811.382244.6684AID686978; AID686979
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.86870.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency28.87020.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency30.76250.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.97850.000229.305416,493.5996AID743075; AID743079
aryl hydrocarbon receptorHomo sapiens (human)Potency7.69590.000723.06741,258.9301AID743122
Histone H2A.xCricetulus griseus (Chinese hamster)Potency57.16700.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency1.25650.010039.53711,122.0200AID588545; AID588547
heat shock protein beta-1Homo sapiens (human)Potency24.65540.042027.378961.6448AID743210
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
Cellular tumor antigen p53Homo sapiens (human)Potency30.58110.002319.595674.0614AID651631; AID651743
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (114)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1348182Anti-Trichomonas activity against Trichomonas vaginalis ATCC 30236 at assessed as inhibition of viable trophozoites number 1 mg/ml after 24 hrs by trypan blue dye-based assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Recent developments in anti-Trichomonas research: An update review.
AID1769590Antibacterial activity against Escherichia coli ATCC 2101123 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based microdilution assay2021Journal of natural products, 06-25, Volume: 84, Issue:6
Mechanistic Insights into the Leishmanicidal and Bactericidal Activities of Batroxicidin, a Cathelicidin-Related Peptide from a South American Viper (
AID1110934Nematicidal activity against juvenile stage of Rhabditis sp. assessed as inhibition of mobility after 20 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1769588Antibacterial activity against Escherichia coli ATCC 25922 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based microdilution assay2021Journal of natural products, 06-25, Volume: 84, Issue:6
Mechanistic Insights into the Leishmanicidal and Bactericidal Activities of Batroxicidin, a Cathelicidin-Related Peptide from a South American Viper (
AID1110932Nematicidal activity against juvenile stage of Heterodera schachtii assessed as inhibition of mobility after 168 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110892Stability of the compound assessed as apperance of new pyrrolizidine alkaloids at 5 mg/mL after 166 hr by thin layer chromatographic analysis under cold temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110927Nematicidal activity against juvenile stage of Meloidogyne incognita (root-knot nematode) assessed as inhibition of mobility incubated for 168 hr followed by compound wash out measured after 24 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110920Repellent activity against juvenile stage of Rhabditis sp. at 0.1 mg/mL after 40 hr by stereomicroscopic analysis (Rvb = 50%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110899Stability of the compound assessed as apperance of pyrroles at 5 mg/mL after 24 to 168 hr by thin layer chromatographic analysis under UV light and hot temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110922Repellent activity against juvenile stage of Rhabditis sp. at 0.1 mg/mL after 20 hr by stereomicroscopic analysis (Rvb = 48%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID339034Cytotoxicity against human A204 cells after 24 hrs by soft agar colony forming assay
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID333842Cytotoxicity against human KB cells
AID1110903Stability of the compound assessed as conversion of free base to N-oxide at 5 mg/mL after 24 to 168 hr by thin layer chromatographic analysis under UV light and hot temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110918Repellent activity against juvenile stage of Meloidogyne incognita (root-knot nematode) at 0.1 mg/mL after 20 hr by stereomicroscopic analysis (Rvb = 50%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110916Repellent activity against juvenile stage of Meloidogyne incognita (root-knot nematode) at 0.1 mg/mL after 40 hr by stereomicroscopic analysis (Rvb = 51%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110923Repellent activity against juvenile stage of Rhabditis sp. at 1 mg/mL after 20 hr by stereomicroscopic analysis (Rvb = 48%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110931Nematicidal activity against juvenile stage of Meloidogyne incognita (root-knot nematode) assessed as inhibition of mobility after 168 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110889Stability of the compound assessed as apperance of new pyrrolizidine alkaloids at 5 mg/mL after 24 hr by thin layer chromatographic analysis under hot temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110902Stability of the compound assessed as apperance of new pyrrolizidine alkaloids at 5 mg/mL after 24 to 168 hr by thin layer chromatographic analysis under UV light and cold temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1110893Stability of the compound assessed as conversion of free base to N-oxide at 5 mg/mL after 24 to 168 hr by thin layer chromatographic analysis under cold temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110936Nematicidal activity against juvenile stage of Meloidogyne incognita (root-knot nematode) assessed as inhibition of mobility after 20 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1110917Repellent activity against juvenile stage of Meloidogyne incognita (root-knot nematode) at 1 mg/mL after 40 hr by stereomicroscopic analysis (Rvb = 51%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110887Stability of the compound assessed as apperance of pyrroles at 5 mg/mL after 166 hr by thin layer chromatographic analysis under hot temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110929Nematicidal activity against juvenile stage of Phasmarhabditis hermaphrodita of assessed as inhibition of mobility after 168 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110919Repellent activity against juvenile stage of Meloidogyne incognita (root-knot nematode) at 1 mg/mL after 20 hr by stereomicroscopic analysis (Rvb = 50%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110888Stability of the compound assessed as apperance of pyrroles at 5 mg/mL after 24 hr by thin layer chromatographic analysis under hot temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110928Nematicidal activity against juvenile stage of Rhabditis sp. assessed as inhibition of mobility after 168 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110904Stability of the compound assessed as apperance of new pyrrolizidine alkaloids at 5 mg/mL after 24 to 168 hr by thin layer chromatographic analysis under UV light and hot temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110935Nematicidal activity against juvenile stage of Pratylenchus penetrans assessed as inhibition of mobility after 20 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1769589Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based microdilution assay2021Journal of natural products, 06-25, Volume: 84, Issue:6
Mechanistic Insights into the Leishmanicidal and Bactericidal Activities of Batroxicidin, a Cathelicidin-Related Peptide from a South American Viper (
AID1110921Repellent activity against juvenile stage of Rhabditis sp. at 1 mg/mL after 40 hr by stereomicroscopic analysis (Rvb = 50%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110930Nematicidal activity against juvenile stage of Pratylenchus penetrans assessed as inhibition of mobility after 168 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110891Stability of the compound assessed as apperance of new pyrrolizidine alkaloids at 5 mg/mL after 166 hr by thin layer chromatographic analysis under hot temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110895Stability of the compound assessed as conversion of free base to N-oxide at 5 mg/mL after 24 to 168 hr by thin layer chromatographic analysis under UV light and cold temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID397122Inhibition of HIV1 RT
AID1769591Antibacterial activity against Escherichia coli ATCC 1812446 assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI protocol based microdilution assay2021Journal of natural products, 06-25, Volume: 84, Issue:6
Mechanistic Insights into the Leishmanicidal and Bactericidal Activities of Batroxicidin, a Cathelicidin-Related Peptide from a South American Viper (
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1110914Ovicidal activity against Meloidogyne incognita (root-knot nematode) assessed as egg hatching at 1 mg/mL after 336 hr (Rvb = 54%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110937Nematicidal activity against juvenile stage of Heterodera schachtii assessed as inhibition of mobility after 20 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110915Ovicidal activity against Meloidogyne incognita (root-knot nematode) assessed as egg hatching at 1 mg/mL after 24 hr (Rvb = 3%)2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110925Nematicidal activity against juvenile stage of Pratylenchus penetrans assessed as inhibition of mobility incubated for 168 hr followed by compound wash out measured after 24 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110890Stability of the compound assessed as apperance of new pyrrolizidine alkaloids at 5 mg/mL after 24 hr by thin layer chromatographic analysis under cold temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110894Stability of the compound assessed as conversion of free base to N-oxide at 5 mg/mL after 24 to 168 hr by thin layer chromatographic analysis under hot temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110933Nematicidal activity against juvenile stage of Phasmarhabditis hermaphrodita of assessed as inhibition of mobility after 20 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110926Nematicidal activity against juvenile stage of Heterodera schachtii assessed as inhibition of mobility incubated for 168 hr followed by compound wash out measured after 24 hr2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1110898Stability of the compound assessed as apperance of pyrroles at 5 mg/mL after 24 to 168 hr by thin layer chromatographic analysis under UV light and cold temperature2009Pest management science, Jul, Volume: 65, Issue:7
Effects of pyrrolizidine alkaloids on the performance of plant-parasitic and free-living nematodes.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,694)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990170 (10.04)18.7374
1990's260 (15.35)18.2507
2000's356 (21.02)29.6817
2010's653 (38.55)24.3611
2020's255 (15.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.26 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index55.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials3 (0.17%)5.53%
Reviews1 (16.67%)6.00%
Reviews28 (1.60%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (0.06%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
Other1,714 (98.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]